



Glances into the Realm of quality by design (QbD) in Pharmaceuticals

Abdurrahman*

Prof. Pramod Kumar Sharma

Ankur Saxena

Department of Medical and Allied Sciences, Galgotias University, Uttar Pradesh, India
School of pharmaceutical sciences, Jaipur national university, Jaipur, Rajasthan, India

Corresponding Authors:

Email:

rahmanpharma02@gmail.com

Abstract:

The aim of this article is to provide the information of pharmaceutical Quality by Design (QbD) and describe how it can be beneficial to pharmaceutical quality. Now a day's QbD is very essential to quality of pharmaceutical product. QbD helps the understanding of industry during product development, particularly building quality in, not testing it. Under QbD when a company design and develop a product it needs to explain Target Product Profile (TPP), Target Product Quality Profile (TPQP) and Critical Quality Attributes (CQA). This is helpful to observe the impact of raw materials Critical Material Attributes (CMA), Critical Process Parameter (CPP) on the CQAs. This empirical approach is very much influential to manufacturing and product development in comparison to the traditional approach. In modern science and typical quality based assessment of pharmaceutical the chemistry, manufacturing, and control of application of ANDA by implementing the QbD, leading to the transformation in case of product development. Finally the company need to improve and enhance their quality by controlling through its manufacturing process in a consistent way.

Keywords: Design Space, Critical Quality Attributes (CQA), Critical Material Attributes (CMA), Target Product Quality Profile (TPQP), Critical Process Parameters (CPP)

INTRODUCTION

A few years back, pharmaceutical companies go through a day by day increasing the difficulty of economic environment. The monetary value related to the manufacturing and development of pharmaceuticals is centered by enhance in the regulatory vault for the approval of new molecule, patent expirations and raised healthcare costs. It has been calculated that most of the pharmaceutical processes function at 2.5-4.5 sigma quality levels, but resource intensifier pharmaceutical company quality systems accomplish 5 sigma quality levels by classifying, retreading to preclude the product having any fault leaving the factory. Conventional development rivet on the formulation and the legal transfer of the product to the succeeding phase of the clinical studies. Mostly the

formulation developments have a tendency to be reiterative and designed through empirical observation. Therefore, changes were forced by the need to alter the process at the time of scale-up or due to the formulation going wrong to come across the hoped shelf life of the product. During phase 3, the developers kept in his mind for very less changes to keep away the call for valuable bioequivalence studies to span between the Clinical Trial Material (CTM) and the commercial product. Therefore, pharmaceutical companies fix their processes and the product quality was assessed by finish product testing. This imminent is ineffective and does not alleviate persistent improvement. Earlier, there also subsisted a belief that the regulatory processes and essentials nixed manufacturing enhancements, which preclude the pharmaceutical industry. The cGMPs introduce for

the 21st century and the publication of the Process Analytical Technology (PAT) counsel in 2004 by the FDA surfaced the way for the pharmaceutical industry making modern. The experts from the

three territorial grouping (USA, EU, and Japan) working on the Quality Topics within ICH produced an imagination for the future pharmaceutical quality system (Fig: 1). (1-5)




Figure 1: ICH vision for the future pharmaceutical quality system (1)

The industry has made forward motion on QbD since the FDA began its 21st Century Quality Initiation, but this is not enough submissions of QbD to date. Contempt the obligating case, the widespread change that the FDA saw has not occurred at the stride that was envisioned. Accomplishing the 21st Century Quality vision will expect a transformative journey for the industry that requires a substantial change in its development process. (6) The pharmaceutical industries function potentially to grow, manufacture, and carry to market new drug and to conform to regulatory needs to declare that the drugs are harmless and efficient. A new approach to drug development possibly will enhance efficiencies, offer regulatory support and flexibility, and propose significant company profit all over the product’s life cycle. Software quality has been a modern approach since the early days of pharmaceutical engineering. Recently, a number of practitioners have shown

great interest in using design patterns for high-quality software. (7-10)

QUALITY BY DESIGN (QbD)

This concept was first drafted by well-known quality expert Joseph M. Juran on Quality by Design. In the former 1990 FDA’s internal discussion began and in 2002 the concept paper on 21st century Good Manufacturing Practice was published.

QbD is defined as, “A systematic approach to development that begins with predefined targets and emphasizes product and process understanding and process control, based on sound science and quality risk management”. (11-15)

Benefits of QbD

Powerfully sharpened on collaboration between research and manufacturing, QbD encourages process realizing for increased potency efficiency. Since QbD convey medicines to patients in a better-understood and

fundamentally more authentic way, consumers benefit as well.

This technique minimizes post approval regulatory submissions, reduces risk around manufacturing failures and product recalls, brings down non-value-added regulatory and abidance activities, and facilitates new approaches to process validation.

QbD idea merged with a growing global industry association that in the direction of building class into pharmaceutical development through manufacturing by major gaps between pharmaceutical development and manufacturing and using have science to elaborate and ensure the safety of product, quality and efficacy overall hole life cycle.

Pharmaceutical companies are interestingly involved in the PQLI initiative. European federation of pharmaceutical industries and association conducted a regulator or industries event around ICH Q8, Q9 and Q10 with the collaboration of pharmaceutical industries. Pharmaceutical industries plays vital role in facilitating this mutual idea. Activities included mock regulatory examination that were conducted at manufacturer's sites and seminars on different topics that included product life cycle management, ahead thinking action and complication. ⁽¹⁶⁾

STEPS OF QBD INVOLVED IN STARTUP PLAN

- Employ a self-sufficient Quality by design expert.
- Appraisal the organization and process with the expert conducting a separate examination.
- Embrace a basic quality by design meeting with your entire special.
- Evaluate the expert's description and proposal.

- Draft an execution plan, timelines and probable expenses.
- Allocate the resources.
- Keep hold of the self-regulating expert as your "project declaration" consultant. ⁽¹⁷⁾

IMPORTANCE OF TPPS AND QTPPS IN PRODUCT DEVELOPMENT

A quality target product profile (QTPP) relates to the mandatory value of a drug product or drug substance that is essential to deliver a desired beneficial outcome. When prepared proactively, the QTPP assists a pre-specified objectives demonstrating product and process deliverables that will offer the maximum benefit for attaining the critical attributes that impact drug product quality.

The QTPP incorporated all the basic attributes a product requirement to deliver in order to meet its proposed use. A product's QTPP renders direction for relating its process, formulation, and incoming materials with therapeutic patient outcome.

Once all of the elements of a QTPP have been defined, a beginning risk evaluation should be concluded before starting development activities. This appropriates for amendment of the QTPP, if needed, and guides development actions previous to deal of major development resources. It is important to note that risk assessments should be updated as further knowledge is gained during development. ⁽¹⁸⁾

CERTAIN FUNDAMENTAL EXPRESSION OF QBD

1. Target Product Profile (TPP)

The TPP forms the basis of design of the product:

- Dosage form
- Route of administration
- Strength
- Release/delivery of the drug

- Pharmacokinetic characteristics (e.g., dissolution; aerodynamic performance)
- Drug product quality criteria (e.g., sterility, purity).

2. Critical Quality Attributes (CQAs)

CQAs deal the physical, chemical, biological, or microbiological property within a suitable limit,

range, or distribution to ensure the desired product quality. This is used to direct the product and process development. In case of solid oral dosage forms usually those aspects affecting product purity, product potency, product stability & drug release.




Figure 2: Key steps in implementation of QbD for a Pharmaceutical Product ⁽²⁴⁾

3. Design Space

It is a multidimensional arrangement and relations of input variables (e.g. material attributes) and process parameters that have been confirmed to provide assurance of quality. If you perform your process within the design space then this will not be regarded as a change. And if processing is performed out of the design space, is considered

to be a change and would normally begin a regulatory post approval amend process.

4. Control Strategy

It is very important to control the material attributes which are in processing viz. drug substance, excipients, and packaging materials on the basis of their impact on process ability or

product quality in-Process controls & end product controls. This control is basically focus on process and formulation understanding that force back the process in the design space based on quality risk management to make certain quality according to specifications.

5. Management and improvement of product lifecycle

The main concern to modify and improve the process within the design space is gathering manufacturing data. At this level, the proposed concepts and rationale for implementing quality by design practices is well understood and accepted. Along of these all, the target is to design a process that fulfills the needs of safety and efficacy for the patient. ⁽¹⁹⁻²³⁾

CONCLUSION

To create a design space parallel to one it is essential to have a detailed understanding of both the characteristics of the formulation and the potential of equipment. One of the key elements of QbD is to prospectively develop in detail process and product understanding, and to relate that understanding to ascertain robust manufacturing processes. From industry perception, even though the QbD approach is estimated to bring about considerable long-term benefits, concerns remain around the increased amount of characterization work that is needed upfront.

REFERENCES

- 1) Gupta Anuj, Dr. Neeraj Kumar Fuloria; "Short review on Quality by design: A new Era of Pharmaceutical drug development",

- International Journal of Drug Development & Research, July- September, 2012; 4(3): 19-26.
- 2) The metamorphosis of manufacturing, IBM Business Consulting Services Executive Briefing, <http://www.ibm.com/services/us/imc/pdf/ge510-4034-metamorphosis-of-manufacturing.pdf>.
- 3) Innovation and continuous improvement in pharmaceutical manufacturing pharmaceutical CGMPs for the 21st Century, U.S. Food and Drug Administration, 2004 September, Available from: URL:<http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf>.
- 4) PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, September 2004,<http://www.fda.gov/cder/guidance/6419f1.pdf>.
- 5) Juran JM. Juran on Quality by Design – The New Steps for Planning Quality into Goods and Services, Free Press, 1992.
- 6) FDA, Understanding Challenges to Quality by Design, Final deliverable for FDA Understanding Challenges to QbD Project December 18, 2009.
- 7) Kumar Sumit, Thakur Shikha, Tanwar Deepika, Baldi Ashish; "A Quantitative Approach for Pharmaceutical Quality by Design Patterns", *Inveti Rapid: Pharm Analysis & Quality Assurance* Vol. 2012, Issue 4: 1-8.
- 8) Davis E, Ierapetritou M. A kriging based method for the resolution of mixed-integer nonlinear programs containing black box functions. *J Glob Optim.* 43(2):191–205, 2009
- 9) Jain S. Mechanical properties of powders for compaction and tableting: an overview. *PSTT*, 2(1):20–31, 1999
- 10) Dubin H. Formulation frustrations. *Drug Deliv. Technol*,5(8):108-114,2005.
- 11) Ashwini Gawade, Satyam Chemate, and Ashwin Kuchekar; "Pharmaceutical Quality by Design: A New Approach in Product Development", *Research and Reviews: Journal*

- of Pharmacy and Pharmaceutical Sciences, July – September, 2013; 2(3): 5-12.
- 12) Food and Drug Administration. Final Report on Pharmaceutical cGMPs for the 21st Century - A Risk Based Approach, http://www.fda.gov/cder/gmp/gmp_2004/GMP_final_report_2004.htm
 - 13) Bhatt D, Rane S. Int J Pharm Pharm Sci. 2011; 3(1).
 - 14) Office of Biotechnology Products, US Food and Drug Administration. Notice of Pilot Program for Submission of Quality Information for Biotechnology Products in the Office of Biotechnology Products, Food Drug Administration, Docket number FDA-2008- N-0355, FDA, Washington, DC 2008.
 - 15) Nars MM, A new pharmaceutical quality assessment system (PQAS)for the 21stcentury,AAPS workshop october 2010.
 - 16) Nwoko Valentine Eziokwu; "Quality by Design (QbD): Manufacturing and Product Quality of Generics Drugs Perspective", International journal of Research and Reviews in Pharmacy and Applied Science, Oct, 2013, 3(5) 590-598.
 - 17) Nishendu P. Nadpara, Rakshit V. Thumar, Vidhi N. Kalola, Parula B. Patel; "Quality by Design (QbD): A Complete Review", International Journal of pharmaceutical Sciences Review and Research, 2012, 17(2) 20-28.
 - 18) Glenn A. Van Buskirk *et al*; "Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm", AAPS Pharm SciTech , Jan,2014.
 - 19) TA. Premchandani, BB. Barik; "Quality by Design: A tool for quality improvement", Journal of Advances in Pharmacy and Healthcare Research, 2011, Issue 1, 7-9.
 - 20) International Conference on Harmonization Guideline ICH Q8 (2)—Pharmaceutical development. November 2008. <http://www.fda.gov/downloads/Drugs/Guidanc>
 - eComplianceRegulatoryInformation/Guidances /UCM073507.pdf.
 - 21) Juran Jm. Juran on quality by designs the new steps for planing quality into goods and services newyork free press 1992 p.no-1-2.
 - 22) www.fda.gov "Quality by Design (QbD) – A Modern System Approach to Pharmaceutical Development and Manufacturing – FDA Perspective" Moheb M. Nasr.
 - 23) <http://www.ich.org> Q8, Q9, Q10 guideline. "Implementation of quality by design in new pharmaceutical development" Peter watmough, gsk.
 - 24) Sandipan Roy; "Quality by Design: A holistic concept of building quality in pharmaceuticals", International journal of PHARMACEUTICAL AND BIOMEDICAL RESEARCH 2012, 3(2), 100-108.

Article History: -----

Date of Submission: 23-05-2014

Date of Acceptance: 04-06-2014

Conflict of Interest: NIL

Source of Support: NONE

